Employers, training providers and community organisationsmet with MSD staff in a campaign to get more people into the workforce. Advertisement Advertise with NZME. Advertisement Advertise with NZME.

MSD is expecting to see an additional $200 million layered onto its costs this year as a result of President Trump's tariffs – even before a possible pharma-specific levy is announced.

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports.

By quantizing weights with different precision for different parts of a network, mixed-precision quantization promises to reduce the hardware cost and improve the speed of deep neural network (DNN) ...

Performance charts for Morgan Stanley Emerging Markets Debt Fund Inc (MSD) including intraday, historical and comparison charts, technical analysis and trend lines.

Objective To assess the comparative efficacy of traditional non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclo-oxygenase-2 inhibitors in patients with acute gout. Design Systematic ...